Loading
A phase 2 trial of Dexamethasone, Daratumumab, Venetoclax in multiple myeloma, run by AbbVie, active and no longer recruiting.
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT03314181 by AbbVie, with 156 participants enrolled, started 2018-04-02 and due to reach its primary completion in 2031-05. Interventions recorded: Dexamethasone, Daratumumab, Venetoclax, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, Daratumumab, Dexamethasone.
Shares BCL-2 inhibitors, Relapsed or refractory multiple myeloma, Venetoclax, Multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/